Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,219
datasets available to search
ShareScore release 0.9.0
Dataset results
1,219 results for “randomisation”
Supplementary file 24 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 24: Proportion of participants on methylphenidate with disturbed sleep</p>
Supplementary file 23 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 23: Proportion of participants on methylphenidate with depression</p>
Supplementary file 42 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 42: Proportion of participants on methylphenidate with tics</p>
Supplementary file 82 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 82: Proportion of participants on methylphenidate with hair loss</p>
Supplementary file 50 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 50: Proportion of participants on methylphenidate with propensity to cry</p>
Supplementary file 40 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 40: Proportion of participants on methylphenidate with excessive talking</p>
Supplementary file 31 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 31: Proportion of participants on methylphenidate with headache </p>
Supplementary file 36 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 36: Proportion of participants on methylphenidate with nightmares </p>
Supplementary file 29 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 29: Proportion of participants on methylphenidate with euphoria/hypomania </p>
Supplementary file 20 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 20: Proportion of participants on methylphenidate with fingernail biting</p>
Supplementary file 73 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 73: Proportion of participants on methylphenidate with nasopharyngitis</p>
Supplementary file 28 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 28: Proportion of participants on methylphenidate with emotional lability</p>
Supplementary file 71 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 71: Proportion of participants on methylphenidate with gastroenteritis</p>
Supplementary file 34 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 34: Proportion of participants on methylphenidate with irritability </p>
Supplementary file 67 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 67: Proportion of participants on methylphenidate with nausea </p>
Data supplement to: "Refractory depression - Mechanisms & Efficacy of Radically Open Dialectical Behaviour Therapy (RefraMED): findings of randomised trial on benefits and harms"
<p>Data and code to support primary analyses reported in "Refractory depression – mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms". British Journal of Psychiatry. doi: 10.1192/bjp.2019.53</p>
Data and code: Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non‐randomised pilot study
<p>This is a dataset and Stata analytical code relating to prescribing issues identified in the GPP pilot feasibility study. The paper reporting this study has been published as follows: </p> <p>Cardwell K, Smith SM, Clyne B on behalf of the General Practice Pharmacist (GPP) Study Group, et al. Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. BMJ Open 2020;10:e035087. doi: 10.1136/bmjopen-2019-035087</p> <p>The abstract of the study is included below:</p> <p><strong>Objective:</strong> Limited evidence suggests integration of pharmacists into the general practice team could improve medicines management for patients, particularly those with multimorbidity and polypharmacy. This study aimed to develop and assess the feasibility of an intervention involving pharmacists, working within general practices, to optimise prescribing in Ireland.</p> <p><strong>Design:</strong> Non-randomised pilot study</p> <p><strong>Setting:</strong> Primary care in Ireland</p> <p><strong>Participants:</strong> Four general practices, purposively sampled and recruited to reflect a range of practice sizes and demographic profiles.</p> <p><strong>Intervention:</strong> A pharmacist joined the practice team for six months (10 hours/week) and undertook medication reviews (face-to-face or chart-based) for adult patients, provided prescribing advice, supported clinical audits, and facilitated practice-based education.</p> <p><strong>Outcome measures:</strong> Anonymised practice-level medication (e.g. medication changes) and cost data were collected. Patient-Reported Outcome Measure (PROM) data were collected on a subset of older adults (aged ≥65 years) with polypharmacy using patient questionnaires, before and six weeks after medication review by the pharmacist.</p> <p><strong>Results:</strong> Across four practices, 787 patients were identified as having 1,521 prescribing issues by the pharmacists. Issues relating to potentially inappropriate or high-risk prescribing were addressed most often by the prescriber (51.8%), compared to cost-related issues (7.5%). Medication changes made during the study equated to approximately €57,000 in cost savings assuming they persisted for 12 months. Ninety-six patients aged ≥65 years with polypharmacy were recruited from the four practices for PROM data collection and 64 (66.7%) were followed up. There were no changes in patients’ treatment burden or attitudes to deprescribing following medication review, and there were conflicting changes in patients' self-reported quality of life.</p> <p><strong>Conclusions:</strong> This non-randomised pilot study demonstrated that an intervention involving pharmacists, working within general practices is feasible to implement and has potential to improve prescribing quality. This study provides rationale to conduct a randomised controlled trial to evaluate the clinical and cost-effectiveness of this intervention.</p>
Fig. 1 in Topical ivermectin is a highly effective seal 'spot-on': A randomised trial of hookworm and lice treatment in the endangered Australian sea lion (Neophoca cinerea)
Fig. 1. Flow diagram of the trial course showing pup recruitment and recapture count for the three experimental groups for each of the three colony visits. P1 = time between recruitment and first recapture; P2 = time between first recapture and second recapture. Observation of deceased pups is shown relative to (i.e., before or after) the pup's sampling at that visit.
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
ClinicalTrials.gov study NCT03991013. IPD Sharing: YES. Countries: 1. Publications: 4.
Data from: A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.